433 related articles for article (PubMed ID: 37638058)
1. Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy.
Zhang M; Lam KP; Xu S
Front Immunol; 2023; 14():1207276. PubMed ID: 37638058
[TBL] [Abstract][Full Text] [Related]
2. Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers.
Boje AS; Pekar L; Koep K; Lipinski B; Rabinovich B; Evers A; Gehlert CL; Krohn S; Xiao Y; Krah S; Zaynagetdinov R; Toleikis L; Poetzsch S; Peipp M; Zielonka S; Klausz K
MAbs; 2024; 16(1):2315640. PubMed ID: 38372053
[TBL] [Abstract][Full Text] [Related]
3. Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers.
Cheng Y; Zheng X; Wang X; Chen Y; Wei H; Sun R; Tian Z; Sun H
Cancer Biol Med; 2020 Nov; 17(4):1026-1038. PubMed ID: 33299651
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments.
Demaria O; Gauthier L; Debroas G; Vivier E
Eur J Immunol; 2021 Aug; 51(8):1934-1942. PubMed ID: 34145579
[TBL] [Abstract][Full Text] [Related]
5. Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia.
Colomar-Carando N; Gauthier L; Merli P; Loiacono F; Canevali P; Falco M; Galaverna F; Rossi B; Bosco F; Caratini M; Mingari MC; Locatelli F; Vivier E; Meazza R; Pende D
Cancer Immunol Res; 2022 Mar; 10(3):291-302. PubMed ID: 35078821
[TBL] [Abstract][Full Text] [Related]
6. Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity.
Gauthier L; Morel A; Anceriz N; Rossi B; Blanchard-Alvarez A; Grondin G; Trichard S; Cesari C; Sapet M; Bosco F; Rispaud-Blanc H; Guillot F; Cornen S; Roussel A; Amigues B; Habif G; Caraguel F; Arrufat S; Remark R; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E
Cell; 2019 Jun; 177(7):1701-1713.e16. PubMed ID: 31155232
[TBL] [Abstract][Full Text] [Related]
7. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.
Vallera DA; Felices M; McElmurry R; McCullar V; Zhou X; Schmohl JU; Zhang B; Lenvik AJ; Panoskaltsis-Mortari A; Verneris MR; Tolar J; Cooley S; Weisdorf DJ; Blazar BR; Miller JS
Clin Cancer Res; 2016 Jul; 22(14):3440-50. PubMed ID: 26847056
[TBL] [Abstract][Full Text] [Related]
8. NKp46-specific single domain antibodies enable facile engineering of various potent NK cell engager formats.
Lipinski B; Arras P; Pekar L; Klewinghaus D; Boje AS; Krah S; Zimmermann J; Klausz K; Peipp M; Siegmund V; Evers A; Zielonka S
Protein Sci; 2023 Mar; 32(3):e4593. PubMed ID: 36775946
[TBL] [Abstract][Full Text] [Related]
9. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.
Huan T; Guan B; Li H; Tu X; Zhang C; Tang B
Hum Vaccin Immunother; 2023 Aug; 19(2):2256904. PubMed ID: 37772505
[TBL] [Abstract][Full Text] [Related]
10. Developing a mechanistic translational PK/PD model for a trifunctional NK cell engager to predict the first-in-human dose for acute myeloid leukemia.
Choi SL; Valente D; Virone-Oddos A; Mauriac C
Clin Transl Sci; 2024 Jan; 17(1):e13689. PubMed ID: 37990450
[TBL] [Abstract][Full Text] [Related]
11. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional NK Cell-Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release.
Klausz K; Pekar L; Boje AS; Gehlert CL; Krohn S; Gupta T; Xiao Y; Krah S; Zaynagetdinov R; Lipinski B; Toleikis L; Poetzsch S; Rabinovich B; Peipp M; Zielonka S
J Immunol; 2022 Nov; 209(9):1724-1735. PubMed ID: 36104113
[TBL] [Abstract][Full Text] [Related]
13. Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.
Schmohl JU; Felices M; Oh F; Lenvik AJ; Lebeau AM; Panyam J; Miller JS; Vallera DA
Cancer Res Treat; 2017 Oct; 49(4):1140-1152. PubMed ID: 28231426
[TBL] [Abstract][Full Text] [Related]
14. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
[TBL] [Abstract][Full Text] [Related]
15. TriKEs and BiKEs join CARs on the cancer immunotherapy highway.
Tay SS; Carol H; Biro M
Hum Vaccin Immunother; 2016 Nov; 12(11):2790-2796. PubMed ID: 27322989
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
17. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
Front Immunol; 2023; 14():1113303. PubMed ID: 37114050
[TBL] [Abstract][Full Text] [Related]
18. Nanobodies in cell-mediated immunotherapy: On the road to fight cancer.
Maali A; Gholizadeh M; Feghhi-Najafabadi S; Noei A; Seyed-Motahari SS; Mansoori S; Sharifzadeh Z
Front Immunol; 2023; 14():1012841. PubMed ID: 36761751
[TBL] [Abstract][Full Text] [Related]
19. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cell-based strategies for immunotherapy of cancer.
Vaněk O; Kalousková B; Abreu C; Nejadebrahim S; Skořepa O
Adv Protein Chem Struct Biol; 2022; 129():91-133. PubMed ID: 35305726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
